Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
It is believed that the body's immune system protects the body by attacking and killing tumor
cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they
recognize special proteins on the surface of tumors. In most patients with advanced cancer,
T-cells are not stimulated enough to kill the tumor. In this research study, we will use a
patient's tumor to make a vaccine which we hope will stimulate T-cells to kill tumor cells
and leave normal cells alone.
High grade gliomas (HGGs) are very aggressive and difficult for the body's immune system to
attack. Before T-cells can become active against tumor cells, they require strong stimulation
by special "stimulator" cells in the body called Dendritic Cells (DCs) which are also part of
the immune system. DCs can recognize the cancer cells and then activate the T lymphocytes,
and create this strong stimulation.
The purpose of this research study is to learn whether anti-tumor T-cells and anti-tumor DC
vaccines can be given safely. Most importantly, this study is also to determine whether the
T-cells and DC vaccines can stimulate a person's immune system to fight off the tumor cells
in the brain.
Phase:
Phase 1
Details
Lead Sponsor:
University of Florida
Collaborators:
Moffitt Clinical Research Network (MCRN) National Cancer Institute (NCI) National Institutes of Health (NIH) National Pediatric Cancer Foundation